🇺🇸#CLVS
Clovis Oncology: Early Clinical Experience From Named-Patient Use Validates Plans to Further Investigate FAP-2286 as a Therapeutic and Imaging Agent Across Variety of Solid Tumor Types

⚠️🇺🇸#CLVS #банкротства
производитель лекарств от рака Clovis подал на банкротство по статье 11

⚠️🇺🇸#CLVS = -11% на банкротстве